StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.87+1.77 (+6.30%)

Close on Nov 17, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma operating margin

Operating margin is operating income as a percentage of revenue.

UroGen Pharma's operating margin for the twelve months ending Jun 30, 2026 was -35.3%. For fiscal 2025 it was -113.7%, against -107.1% the year before. The highest annual figure on record is 4.6% in fiscal 2016.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-113.7%−6.7
FY2024Dec 31, 2024-107.1%−27.8
FY2023Dec 31, 2023-79.2%+43.6
FY2022Dec 31, 2022-122.8%+69.3
FY2021Dec 31, 2021-192.1%+882.0
FY2020Dec 31, 2020-1074.2%+607137.0
FY2019Dec 31, 2019-608211.1%−601368.9
FY2018Dec 31, 2018-6842.2%−6597.7
FY2017Dec 31, 2017-244.5%−249.1
FY2016Dec 31, 20164.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 20260.2%+171.3
Q1 FY2026Mar 31, 2026-39.8%+142.5
Q4 FY2025Dec 31, 2025-50.5%+62.1
Q3 FY2025Sep 30, 2025-99.7%−30.0
Q2 FY2025Jun 30, 2025-171.2%−52.9
Q1 FY2025Mar 31, 2025-182.3%−45.2
Q4 FY2024Dec 31, 2024-112.6%−50.5
Q3 FY2024Sep 30, 2024-69.6%−4.9
Q2 FY2024Jun 30, 2024-118.3%−45.5
Q1 FY2024Mar 31, 2024-137.1%−8.8
Q4 FY2023Dec 31, 2023-62.1%+50.0
Q3 FY2023Sep 30, 2023-64.7%+47.6
Q2 FY2023Jun 30, 2023-72.8%+39.9
Q1 FY2023Mar 31, 2023-128.2%+33.6
Q4 FY2022Dec 31, 2022-112.1%+11.0
Q3 FY2022Sep 30, 2022-112.4%+94.1
Q2 FY2022Jun 30, 2022-112.7%+62.4
Q1 FY2022Mar 31, 2022-161.9%+187.0
Q4 FY2021Dec 31, 2021-123.1%+219.0
Q3 FY2021Sep 30, 2021-206.5%+635.0
Q2 FY2021Jun 30, 2021-175.1%+8373.3
Q1 FY2021Mar 31, 2021-348.9%+131612.2
Q4 FY2020Dec 31, 2020-342.1%+7109.8
Q3 FY2020Sep 30, 2020-841.5%+4222.8
Q2 FY2020Jun 30, 2020-8548.4%−5712.6
Q2 FY2019Jun 30, 2019-131961.1%−128854.7
Q3 FY2018Sep 30, 2018-7451.9%−7448.1
Q2 FY2018Jun 30, 2018-5064.3%+13556.8
Q1 FY2018Mar 31, 2018-2835.8%–
Q4 FY2017Dec 31, 2017-3106.4%–
Q3 FY2017Sep 30, 2017-3.9%–
Q1 FY2017Mar 31, 2017-18621.1%–

More UroGen Pharma figures

See a number that looks wrong?